title: Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.
abstract: Serum bactericidal activity (SBA) and ELISA antibody levels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled trial involving 408 15- to 20-year-olds. Subjects were given two doses at a 6-week interval of a serogroup B or control vaccine. Response was defined as > or = 4-fold rise in antibody level. After two doses of the Finlay Institute (Havana) vaccine at 12 months, the proportions of SBA and ELISA responders were not different from those of the control group (15% and 17% [vaccine] vs. 13% and 9% [control], P > .05). After two doses of the National Institute of Public Health (Oslo) vaccine, there were more SBA and ELISA responders than in the control group (47% and 34% [vaccine] vs. 10% and 1% [control]) or the Finlay Institute vaccine group (P < .05 for both). SBA and ELISA may be insensitive correlates for protective efficacy for some outer membrane protein-based serogroup B meningococcal vaccines.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. BAP4@cdc.gov
authors.forename: B A
authors.initials: BA
authors.lastname: Perkins
authors.forename: K
authors.initials: K
authors.lastname: Jonsdottir
authors.forename: H
authors.initials: H
authors.lastname: Briem
authors.forename: E
authors.initials: E
authors.lastname: Griffiths
authors.forename: B D
authors.initials: BD
authors.lastname: Plikaytis
authors.forename: E A
authors.initials: EA
authors.lastname: Hoiby
authors.forename: E
authors.initials: E
authors.lastname: Rosenqvist
authors.forename: J
authors.initials: J
authors.lastname: Holst
authors.forename: H
authors.initials: H
authors.lastname: Nokleby
authors.forename: F
authors.initials: F
authors.lastname: Sotolongo
authors.forename: G
authors.initials: G
authors.lastname: Sierra
authors.forename: H C
authors.initials: HC
authors.lastname: Campa
authors.forename: G M
authors.initials: GM
authors.lastname: Carlone
authors.forename: D
authors.initials: D
authors.lastname: Williams
authors.forename: J
authors.initials: J
authors.lastname: Dykes
authors.forename: D
authors.initials: D
authors.lastname: Kapczynski
authors.forename: E
authors.initials: E
authors.lastname: Tikhomirov
authors.forename: J D
authors.initials: JD
authors.lastname: Wenger
authors.forename: C V
authors.initials: CV
authors.lastname: Broome
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use*; D001770:Blood Bactericidal Activity; D002353:Carrier State; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007055:Iceland; D008297:Male; D008589:Meningococcal Infections / Q000517:prevention & control*; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology; D012107:Research Design; D012703:Serotyping
chemical_list: D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines